NIOX GroupCSSPF 77 3-Year ROIIC % is -19.02 as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 801 Medical Devices & Instruments companies, NIOX Group ranks worse than 67.79% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
NIOX Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -19.02%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for NIOX Group's 3-Year ROIIC % or its related term are showing as below:
CSSPF's 3-Year ROIIC % is ranked worse than 67.79% of 801
companies
in the Medical Devices & Instruments industry
Industry Median: 1.27
vs CSSPF: -19.02
NIOX Group (OTCPK:CSSPF) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
NIOX Group 3-Year ROIIC % Related Terms
NIOX Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for NIOX Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group 3-Year ROIIC % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where NIOX Group's 3-Year ROIIC % falls into.
NIOX Group's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 8.9525 (Dec. 2025) - 2.192 (Dec. 2022) )
/
( 69.076 (Dec. 2025) - 94.154 (Dec. 2022) )
=
6.7605
/
-25.078
=
-26.96%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
NIOX Group (CSSPF) has a 3-Year ROIIC % of -19.02 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #543 out of 801 companies in the Medical Devices & Instruments industry, placing it in the top 67.8%.
Is NIOX Group's 3-Year ROIIC % too high?
NIOX Group's current 3-Year ROIIC % is -19.02. Based on the distribution chart, NIOX Group ranks #543 out of 801 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's 3-Year ROIIC % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #543 out of 801 companies for 3-Year ROIIC %. This places NIOX Group in the lower half of its industry. The industry median 3-Year ROIIC % is 1.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Devices & Instruments company?
The median 3-Year ROIIC % among Medical Devices & Instruments companies is 1.27, based on 801 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median 3-Year ROIIC % is 1.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current 3-Year ROIIC % is -19.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current 3-Year ROIIC % is -19.02. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For NIOX Group (CSSPF), the current 3-Year ROIIC % is -19.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
3-Year ROIIC %: -19.02
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
